Decade Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History

Decade Capital Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-80,000	Closed	-$1.3M	–	175
2014 Q4	$1.3M	Sell	80,000 -320,000	-80%	-$5.87M	0.22%	94
2014 Q3	$8.83M	Sell	400,000 -258,934	-39%	-$5.3M	1.03%	31
2014 Q2	$13.3M	Buy	658,934 +8,934	+1%	+$151K	1.32%	26
2014 Q1	$12.1M	Buy	+650,000	New	+$8.95M	0.81%	39

Other funds holding AMRI

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VNIM

Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return

OWP

Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Decade Capital Management's AMRI Position: Q1 2015 in Review

Decade Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q1 2015, closing a stake of 80,000 shares — an estimated $1.3M sold.

Decade Capital Management first reported a position in AMRI in Q1 2014 and held it in 4 quarters. The position peaked at $13.3M in Q2 2014. 131 funds tracked by Wall St. Rank hold AMRI as of Q1 2015.

Decade Capital Management reported no remaining Albany Molecular Research Inc position as of Q1 2015 after selling out during the quarter.
Decade Capital Management sold 80,000 Albany Molecular Research Inc shares in Q1 2015, an estimated $1.3M.
Decade Capital Management first reported a position in Albany Molecular Research Inc in Q1 2014 and held it in 4 quarters.
Decade Capital Management's Albany Molecular Research Inc position peaked at $13.3M in Q2 2014.
131 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2015.

Based on Decade Capital Management's 13F filing for Q1 2015, filed 15 May 2015.